clonoSEQ is now covered by Medicare for MCL patients.
It is the first Medicare-reimbursed MRD test for patients with MCL and is clinically available as a CLIA-validated LDT.
For more information about incorporating clonoSEQ into your clinical practice for MCL patients, click here.

Gain a clearer perspective of your patient's cancer.

clonoSEQ is a measurable residual disease (MRD) test that detects, quantifies, and assesses the small number of cancer cells that may remain in a patient’s body during and after treatment.1 Use clonoSEQ to watch changes in cancer with a keen eye, so you and your patient can get the most out of today’s advanced therapies.

Learn more about clonoSEQ

Disease burden changes over time. Keep it in your sights with clonoSEQ.

Enhance your view of cancer with valuable insights at crucial care timepoints. Using clonoSEQ throughout treatment provides clarity that enables you to take action when it matters most.

See the value of testing over time

Simple blood-based testing

Stay on top of changes in disease burden, potentially exposing patients to fewer bone marrow draws.2-6

Deeply sensitive

Reliably measuring MRD at 10-6*, the greatest depth of detection currently available.1,7,8†

Broadly validated

FDA-cleared in myeloma, CLL, and ALL. CLIA-validated in DLBCL, MCL, and other lymphoid cancers.

Ready for clonoSEQ in your practice?

Learn how to order

Covered by Medicare and most commercial insurance.

clonoSEQ is nationally covered by Medicare for multiple myeloma, ALL, CLL, DLBCL, and MCL, and has positive coverage policies for multiple myeloma and ALL from the largest national private insurers.‡ Experience our dedication to making clonoSEQ available and affordable to all who need it with Adaptive Assist™, our patient support program that provides broad billing support tailored to each patient’s needs.

Learn more about Adaptive Assist

90%

of patients pay $0
for clonoSEQ§

Learn more about Adaptive Assist

ctDNA, circulating tumor DNA; MCL, mantle cell lymphoma.
*Given sufficient sample material.
†For multiple myeloma, CLL, and ALL. For DLBCL, clonoSEQ identifies ctDNA in the blood, detecting residual disease at a sensitivity of a single tumor molecule.
‡Full coverage policy details for clonoSEQ can be accessed at the CMS website at https://go.cms.gov/2GL4Ej5. Please refer to www.clonoseq.com/resources-and-support/downloadable-resources for more information or to download an ABN template.
§Prior to enrolling in the Adaptive Assist Patient Financial Assistance Program.

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020.
  2. Frank M, et al. J Clin Oncol. 2021;39(27):3034-3043.
  3. Thompson P, et al. Blood. 2019;134(22):1951-1959.
  4. Vij R, et al. Clin Lymphoma Myeloma Leuk. 2014;14(2):131-139.e1.
  1. Muffly L, et al. Paper presented at: the 62nd ASH Annual Meeting and Exposition; December 5-8, 2020; virtual. Abstract 975.
  2. Muffly L, et al. Blood Adv. 2021;5(16):3147-3151.
  3. Short N, et al. Am J Hematol. 2019;94:257-265. 
  4. Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.